These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


173 related items for PubMed ID: 7596121

  • 1. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators.
    Grünberg B, Kruse HJ, Negrescu EV, Siess W.
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):545-51. PubMed ID: 7596121
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
    Negrescu EV, Grünberg B, Kratzer MA, Lorenz R, Siess W.
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
    [Abstract] [Full Text] [Related]

  • 4. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH, Haslam RJ.
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [Abstract] [Full Text] [Related]

  • 5. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells.
    Eigenthaler M, Nolte C, Halbrügge M, Walter U.
    Eur J Biochem; 1992 Apr 15; 205(2):471-81. PubMed ID: 1315268
    [Abstract] [Full Text] [Related]

  • 6. Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost.
    Reep BR, Lapetina EG.
    Biochem Biophys Res Commun; 1996 Feb 06; 219(1):1-5. PubMed ID: 8619788
    [Abstract] [Full Text] [Related]

  • 7. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
    Bowen R, Haslam RJ.
    J Cardiovasc Pharmacol; 1991 Mar 06; 17(3):424-33. PubMed ID: 1711604
    [Abstract] [Full Text] [Related]

  • 8. Endothelium-dependent phosphorylation of vasodilator-stimulated protein in platelets during coronary passage.
    Pohl U, Nolte C, Bunse A, Eigenthaler M, Walter U.
    Am J Physiol; 1994 Feb 06; 266(2 Pt 2):H606-12. PubMed ID: 8141362
    [Abstract] [Full Text] [Related]

  • 9. Vasodilator-Stimulated Phosphoprotein (VASP)-dependent and -independent pathways regulate thrombin-induced activation of Rap1b in platelets.
    Benz PM, Laban H, Zink J, Günther L, Walter U, Gambaryan S, Dib K.
    Cell Commun Signal; 2016 Sep 13; 14(1):21. PubMed ID: 27620165
    [Abstract] [Full Text] [Related]

  • 10. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA, Lawrence RA, Jones RL, Wilson NH, Collier A.
    Br J Pharmacol; 1989 Jul 13; 97(3):657-68. PubMed ID: 2474350
    [Abstract] [Full Text] [Related]

  • 11. Novel roles of cAMP/cGMP-dependent signaling in platelets.
    Smolenski A.
    J Thromb Haemost; 2012 Feb 13; 10(2):167-76. PubMed ID: 22136590
    [Abstract] [Full Text] [Related]

  • 12. Phosphorylation of rap1B by protein kinase A is not involved in platelet inhibition by cyclic AMP.
    Siess W, Grünberg B.
    Cell Signal; 1993 Mar 13; 5(2):209-14. PubMed ID: 7684600
    [Abstract] [Full Text] [Related]

  • 13. Intracellular levels of cyclic AMP and cyclic GMP differentially modify platelet aggregate size in human platelets activated with epinephrine or ADP.
    Qi R, Ozaki Y, Satoh K, Yang LB, Asazuma N, Yatomi Y, Kume S.
    J Cardiovasc Pharmacol; 1996 Aug 13; 28(2):215-22. PubMed ID: 8856476
    [Abstract] [Full Text] [Related]

  • 14. Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.
    Boese M, Busse R, Mülsch A, Schini-Kerth V.
    Br J Pharmacol; 1996 Oct 13; 119(4):707-15. PubMed ID: 8904645
    [Abstract] [Full Text] [Related]

  • 15. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies.
    Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J.
    Stroke; 2003 Mar 13; 34(3):764-9. PubMed ID: 12624305
    [Abstract] [Full Text] [Related]

  • 16. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP.
    Alheid U, Reichwehr I, Förstermann U.
    Eur J Pharmacol; 1989 May 02; 164(1):103-10. PubMed ID: 2546782
    [Abstract] [Full Text] [Related]

  • 17. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
    Nolte C, Eigenthaler M, Horstrup K, Hönig-Liedl P, Walter U.
    Biochem Pharmacol; 1994 Oct 18; 48(8):1569-75. PubMed ID: 7980622
    [Abstract] [Full Text] [Related]

  • 18. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A, Michael-Hepp J, Meyer J, Darius H.
    Eur J Pharmacol; 1995 May 26; 289(3):455-61. PubMed ID: 7556414
    [Abstract] [Full Text] [Related]

  • 19. Potentiating effect of 3-isobutyryl-2-isopropylpyrazolo-[1,5a]-pyridine (KC-404), a new cerebral vasodilator with anti-platelet activity, on prostacyclin-induced increase of cyclic AMP content in platelets of rat.
    Hisayama T, Takayanagi I, Goromaru N, Okamoto Y.
    Gen Pharmacol; 1989 May 26; 20(2):183-6. PubMed ID: 2541044
    [Abstract] [Full Text] [Related]

  • 20. Endothelial cell-dependent phosphorylation of a platelet protein mediated by cAMP- and cGMP-elevating factors.
    Nolte C, Eigenthaler M, Schanzenbächer P, Walter U.
    J Biol Chem; 1991 Aug 05; 266(22):14808-12. PubMed ID: 1650367
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.